Senti Biosciences Inc
NASDAQ:SNTI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.03
5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
S
|
Senti Biosciences Inc
NASDAQ:SNTI
|
28.4m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
387.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.9B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.2B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Senti Biosciences Inc
Glance View
Senti Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California. The company went IPO on 2021-05-26. Senti Biosciences Inc., formerly Dynamics Special Purpose Corp., is a pre-clinical biotechnology company. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.